Ahmed Ahmed
MBBCH, MSc, MD, MRCOG, PhD
Professor of Gynaecological Oncology
- Consultant Gynaecological Oncology Surgeon
- Director of the Ovarian Cancer Cell Laboratory at the Weatherall Institute of Molecular Medicine
Research groups
Latest Paper
The Repertoire of Serous Ovarian Cancer Non-genetic Heterogeneity Revealed by Single-Cell Sequencing of Normal Fallopian Tube Epithelial Cells Click here to read
Click here to watch video: "Scientists closer to finding the cell of origin for ovarian cancer"
BIOGRAPHY
I am a Professor of Gynaecological Oncology at the Nuffield Department of Women's & Reproductive Health at the University of Oxford and a Consultant Gynaecological Oncology Surgeon at the Oxford Cancer and Haematology Centre and is a Fellow of St Hugh’s College. I lead laboratory-based translational research in Gynaecological Oncology. My main research interest is in the surgical, medical and fundamental research into ovarian cancer. I graduated from Ain Shams University in Cairo, Egypt and completed my PhD and Gynaecological Oncology Surgical training at the University of Cambridge. I received my postdoctoral research training at the University of Cambridge and at the University of Texas, M.D. Anderson Cancer Centre in the USA. I was appointed as a Clinical Reader in Oxford in 2010 and became a Medical Research Council Senior Clinical Research Fellow at the Weatherall Institute of Molecular Medicine and Professor of Gynaecological Oncology in 2012.
Colleges
Key publications
-
The Repertoire of Serous Ovarian Cancer Non-genetic Heterogeneity Revealed by Single-Cell Sequencing of Normal Fallopian Tube Epithelial Cells.
Journal article
Hu Z. et al, (2020), Cancer Cell, 37, 226 - 242.e7
-
A highly accurate platform for clone-specific mutation discovery enables the study of active mutational processes.
Journal article
KaramiNejadRanjbar M. et al, (2020), Elife, 9
-
Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies.
Journal article
Hellner K. et al, (2016), EBioMedicine, 10, 137 - 149
-
Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche.
Journal article
Miranda F. et al, (2016), Cancer Cell, 30, 273 - 289
-
SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer.
Journal article
Ahmed AA. et al, (2010), Cancer Cell, 18, 109 - 121
-
Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation.
Journal article
Zheng Y. et al, (2018), Nat Commun, 9
-
A pan-cancer genome-wide analysis reveals tumour dependencies by induction of nonsense-mediated decay.
Journal article
Hu Z. et al, (2017), Nat Commun, 8
-
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.
Journal article
Ahmed AA. et al, (2010), J Pathol, 221, 49 - 56
-
Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference.
Journal article
Bast RC. et al, (2019), Cancer, 125, 1963 - 1972
-
Enhanced Immunogenicity of Mitochondrial-Localized Proteins in Cancer Cells.
Conference paper
Prota G. et al, (2020), Cancer Immunol Res, 8, 685 - 697
Recent publications
-
Oxford Classic-defined EMT risk stratification of High Grade Serous Ovarian cancer for guiding treatment decisions
Journal article
Rai L. et al, (2025), Clinical Cancer Research
-
LCN2-mediated ferroptosis resistance in tissue homeostasis and early-stage tumorigenesis of the fallopian tube epithelium
Journal article
Imaeda K. et al, (2025), iScience, 112654 - 112654
-
3D Microtumors Representing Ovarian Cancer Minimal Residual Disease Respond to the Fatty Acid Oxidation Inhibitor Perhexiline.
Journal article
Yang X. et al, (2025), Adv Healthc Mater